Table 4. Trials reporting treatment-related deaths and causes of deaths.

First author	Year	Study drug	PD-1/PD-L1	Events	Total number of patients	Causes of deaths
Besse	2015	Atezolizumab	PD-L1	1	659	Pneumonia
Fehrenbacher	2016	Atezolizumab	PD-L1	1	142	Cardiac failure
Gulley	2015	Avelumab	PD-L1	3	184	Radiation pneumonitis, acute respiratory failure, disease progression
Horn	2015	Atezolizumab	PD-L1	1	88	Cardiorespiratory arrest
Spigel	2015	Atezolizumab	PD-L1	1	137	Constrictive pericarditis
Borghaei	2015	Nivolumab	PD-1	1	287	Encephalitis
Brahmer	2012	Nivolumab	PD-1	1	75	Pulmonary toxicity
Brahmer	2012	Nivolumab	PD-1	2	207	Disease progression
Gettinger	2015	Nivolumab	PD-1	1	129	Pneumonitis
Rizvi	2015	Nivolumab	PD-1	2	117	Pneumonia, ischemic stroke
Soria	2015	Pembrolizumab	PD-1	3	449	Cardiorespiratory arrest, ILD, respiratory arrest
Topalian	2012	Nivolumab	PD-1	3	296	Study drug toxicity
Garon	2015	Pembrolizumab	PD-1	1	495	Interstitial lung disease
Herbst	2016	Pembrolizumab	PD-1	6	682	2 mg/kg (pneumonitis, pneumonia), 10 mg/kg (myocardial infarction, pneumonitis, pneumonia)
Langer	2016	Pembrolizumab	PD-1	1	59	Sepsis
Reck	2016	Pembrolizumab	PD-1	1	154	Unknown cause

PD-1, programmed death-1; PD-L1, programmed death ligand-1; ILD, interstitial lung disease.